HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women.
Seneviratne HK et al. 2020. https://pubmed.ncbi.nlm.nih.gov/33191765/ Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076) . AIDS Res Hum Retroviruses.
Bekker LG, et al. 2020. https://pubmed.ncbi.nlm.nih.gov/32280940/ Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women . EClinicalMedicine.
Tolley EE, et. al. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813716/ Acceptability of a long-acting injectable HIV prevention product among us and african women: Findings from a phase 2 clinical trial (HPTN 076) . J Int AIDS Soc.